OPB 111001
Alternative Names: OPB-111001Latest Information Update: 28 Feb 2018
At a glance
- Originator Otsuka Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Prostate cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Tablet)
- 15 Feb 2016 Phase-I development for Solid tumours is ongoing in European Union (PO)
- 28 Apr 2015 Otsuka suspends a phase I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in United Kingdom (NCT02042885)